denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Hematology Disease Topics & Pathways:
Research, Clinical Research, Chronic Myeloid Malignancies, Diseases, Lymphoid Malignancies, Myeloid Malignancies
Description:
Myeloproliferative neoplasms (MPNs), including essential thrombocytosis (ET), polycythemia vera (PV), and myelofibrosis (MF) are hematopoietic stem cell neoplasms with heterogeneous clinical features and outcomes, but a common pathogenic driver: JAK/STAT pathway activation. Despite the development of JAK pathway inhibitors, many clinical challenges and unmet needs persist in the MPN field. This educational session will focus on actively evolving areas of MPN clinical management and research, including molecular prognostication across MPN subtypes, management of cytopenic MF, and approaches to accelerated or blast phase MPNs.
Dr. Alessandro Maria Vannucchi will outline the most frequent chromosomal and mutation abnormalities detected in chronic MPNs and discuss the evidence, in some instances still limited, that such knowledge might inform clinical decision making. By using an instructive clinical case, he will highlight how molecular-integrated risk score systems might enhance the identification of patients with myelofibrosis and poor prognosis, as compared to conventional clinical scores, facilitating their referral to stem cell transplantation.
Dr. Kristen Pettit will focus on a phenotypically distinct subset of MF, termed "cytopenic MF." She will present the clinical features, outcomes, and limitations unique to cytopenic MF. She will also discuss new and emerging strategies to treat this distinct and challenging disease state.
Dr. Raajit Rampal will review the clinical features of accelerated or blast phase MPNs, and discuss pathologic drivers of MPN evolution towards these more aggressive disease states. He will discuss current treatment options for accelerated of blast phase MPNs, highlighting novel therapeutic options as well as the need for more effective therapies.
Dr. Alessandro Maria Vannucchi will outline the most frequent chromosomal and mutation abnormalities detected in chronic MPNs and discuss the evidence, in some instances still limited, that such knowledge might inform clinical decision making. By using an instructive clinical case, he will highlight how molecular-integrated risk score systems might enhance the identification of patients with myelofibrosis and poor prognosis, as compared to conventional clinical scores, facilitating their referral to stem cell transplantation.
Dr. Kristen Pettit will focus on a phenotypically distinct subset of MF, termed "cytopenic MF." She will present the clinical features, outcomes, and limitations unique to cytopenic MF. She will also discuss new and emerging strategies to treat this distinct and challenging disease state.
Dr. Raajit Rampal will review the clinical features of accelerated or blast phase MPNs, and discuss pathologic drivers of MPN evolution towards these more aggressive disease states. He will discuss current treatment options for accelerated of blast phase MPNs, highlighting novel therapeutic options as well as the need for more effective therapies.